Overseas Chinese Equities, Aequitas Research

Ming Lu

Overseas Chinese Equities

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>Xiaomi released healthy financial results inspite of the shrinking market.</li>
<li>Alibaba Freshippo founder, Mr. Hou, retired from his role as the CEO of Freshippo.</li>
<li>JD began to provide aftermarket service to BYD, the largest new energy vehicle producer.</li>
</ul>


Xiaomi released healthy financial results inspite of the shrinking market.
Alibaba Freshippo founder, Mr. Hou, retired from his role as the CEO of Freshippo.
JD began to provide aftermarket service to BYD, the largest new energy vehicle producer.


China Consumption Weekly (25 Mar 2024): Xiaomi, Alibaba, Xpeng, Maoyan, JD Health, JD.com

Blue Lotus Non US Internet research, Blue Lotus Research Institute

Ying Pan

Blue Lotus Non US Internet research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>SHEIN/PDD: France to restrict sales of fast - fashion (-/-)</li>
<li>NTES: After The Release of The New Expansion Pack For &lt;Beyond the World&gt;, It Climbed to the 3rd Position on iOS Games Grossing Chart in China (+)</li>
<li>6618 HK：JD Health's revenue in 2H23 exceeded expectations, while profits fell short, and revenue and profit guidance for 2024 both worse than consensus（-）</li>
</ul>


SHEIN/PDD: France to restrict sales of fast - fashion (-/-)
NTES: After The Release of The New Expansion Pack For &lt;Beyond the World&gt;, It Climbed to the 3rd Position on iOS Games Grossing Chart in China (+)
6618 HK：JD Health's revenue in 2H23 exceeded expectations, while profits fell short, and revenue and profit guidance for 2024 both worse than consensus（-）


[Blue Lotus Daily - TMT Update]:SHEIN/PDD/NTES/6618 HK

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

160 Health International / Equity Capital Markets

<ul>
<li>160 Health collaborates with medical institutions and then get access to high-caliber medical professionals, which helps to attract patients/other business parties. So, its business model is B2B2C, similar to ClouDr.</li>
<li>However, ClouDr has much better performance than 160 Health, because ClouDr has established moat/barriers to more effectively monetize medical resources, while 160 Health is clearly lagging behind in this regard.</li>
<li>160 Health’s revenue mainly comes from sales of pharmaceutical and healthcare products, whose gross margin is very low. As the competition intensifies, the C-end customer acquisition cost would also increase.  </li>
</ul>


160 Health collaborates with medical institutions and then get access to high-caliber medical professionals, which helps to attract patients/other business parties. So, its business model is B2B2C, similar to ClouDr.
However, ClouDr has much better performance than 160 Health, because ClouDr has established moat/barriers to more effectively monetize medical resources, while 160 Health is clearly lagging behind in this regard.
160 Health’s revenue mainly comes from sales of pharmaceutical and healthcare products, whose gross margin is very low. As the competition intensifies, the C-end customer acquisition cost would also increase.  


Pre-IPO 160 Health - The Lack of Moat Has Led to Development Falling Far Short of Expectations

Ping An Healthcare and Technology / Equity Bottom-Up

<ul>
<li>Fang Weihao's departure means PAGD's strategic transformation failed. The business model of being a "vassal" of Ping An Group seems hard to bring high valuation due to “discounted” growth potential.</li>
<li>PAGD is at a crossroads. The question is which development path will the new CEO choose - Follow Fang Weihao's strategy or return to the traditional Internet healthcare business model?</li>
<li>Both directions have painful costs that investors will not be happy with. Therefore, we recommend that investors remain sober and rational in the face of the bullish view on PAGD.</li>
</ul>


Fang Weihao's departure means PAGD's strategic transformation failed. The business model of being a "vassal" of Ping An Group seems hard to bring high valuation due to “discounted” growth potential.
PAGD is at a crossroads. The question is which development path will the new CEO choose - Follow Fang Weihao's strategy or return to the traditional Internet healthcare business model?
Both directions have painful costs that investors will not be happy with. Therefore, we recommend that investors remain sober and rational in the face of the bullish view on PAGD.


Ping An Healthcare and Technology (1833.HK) - Valuation Logic May Completely Change Due to New Path

Beijing Yuanxin Technology Group Co Ltd / Equity Capital Markets

<ul>
<li>The essence of Yuanxin's business is selling drugs.Although Yuanxin is backed by Tencent, it’s difficult to come up with more outstanding advantages to compete with Alibaba Health and JD Health.</li>
<li>We have doubts about Yuanxin’s core competitiveness and sustainable profitability, which are also far behind its peers. In our view, the market/investors may find it difficult to accept such stories.</li>
<li>Pre-IPO valuation level of Yuanxin has greatly exceeded the valuation of its drugstore business model. Yuanxin’s valuation should be lower than peers, or for example, P/S ratio of below 1x.</li>
</ul>


The essence of Yuanxin's business is selling drugs.Although Yuanxin is backed by Tencent, it’s difficult to come up with more outstanding advantages to compete with Alibaba Health and JD Health.
We have doubts about Yuanxin’s core competitiveness and sustainable profitability, which are also far behind its peers. In our view, the market/investors may find it difficult to accept such stories.
Pre-IPO valuation level of Yuanxin has greatly exceeded the valuation of its drugstore business model. Yuanxin’s valuation should be lower than peers, or for example, P/S ratio of below 1x.


Pre-IPO Beijing Yuanxin Technology Group (PHIP Update) - Risk of Overvaluation and Poor Profit Model

China

JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health International (6618 HK)

China Consumption Weekly (25 Mar 2024): Xiaomi, Alibaba, Xpeng, Maoyan, JD Health, JD.com

Xiaomi released healthy financial results despite of the shrinking market. Alibaba Freshippo founder retired. JD began to provide aftermarket...

Ming Lu

[Blue Lotus Daily - TMT Update]:SHEIN/PDD/NTES/6618 HK

France to restrict sales of fast-fashion; JD Health's revenue exceeds expectations but profits fall short with worse guidance for 2024. NTES...

Blue Lotus Research Institute

Pre-IPO 160 Health - The Lack of Moat Has Led to Development Falling Far Short of Expectations

160 Health’s B2B2C business model is logical, but rich medical resources can't be effectively translated into performance. Whichever business...

Xinyao (Criss) Wang

Ping An Healthcare and Technology (1833.HK) - Valuation Logic May Completely Change Due to New Path

The core of future development of PAGD is not who the CEO is, but what kind of development path it will take. Valuation logic would change...

Xinyao (Criss) Wang

Pre-IPO Beijing Yuanxin Technology Group (PHIP Update) - Risk of Overvaluation and Poor Profit Model

The dilemma of single revenue model and excessive reliance on drug sales is hard to overcome.Due to low gross margin, it's difficult to generate...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Consumption Weekly (25 Mar 2024): Xiaomi, Alibaba, Xpeng, Maoyan, JD Health, JD.com

Xiaomi released healthy financial results despite of the shrinking market. Alibaba Freshippo founder retired. JD began to provide aftermarket...

Ming Lu

[Blue Lotus Daily - TMT Update]:SHEIN/PDD/NTES/6618 HK

​France to restrict sales of fast-fashion; JD Health's revenue exceeds expectations but profits fall short with worse guidance for 2024. NTES...

Blue Lotus Research Institute

Pre-IPO 160 Health - The Lack of Moat Has Led to Development Falling Far Short of Expectations

160 Health’s B2B2C business model is logical, but rich medical resources can't be effectively translated into performance. Whichever business...

Xinyao (Criss) Wang

Ping An Healthcare and Technology (1833.HK) - Valuation Logic May Completely Change Due to New Path

The core of future development of PAGD is not who the CEO is, but what kind of development path it will take. Valuation logic would change...

Xinyao (Criss) Wang

Pre-IPO Beijing Yuanxin Technology Group (PHIP Update) - Risk of Overvaluation and Poor Profit Model

The dilemma of single revenue model and excessive reliance on drug sales is hard to overcome.Due to low gross margin, it's difficult to generate...

Xinyao (Criss) Wang

France to restrict sales of fast-fashion; JD Health's revenue exceeds expectations but profits fall short with worse guidance for 2024. NTES...